PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩1,000 per share · Prices as of the 2026-10-02 close
Dai Han Pharmaceutical, a leading domestic maker of IV infusion fluids and ampoule injections, saw its operating margin compress in 2025 due to cost pressure, but quarterly profitability has shown signs of recovery through the first half of 2026.
2025 consolidated revenue rose to KRW 208.6 billion, a fourth straight annual increase, but operating profit declined year over year as the operating margin fell from 18.6% to 14.9%.
Operating profit dropped sharply to KRW 3.57 billion in Q4 2025 before recovering to KRW 7.86 billion in Q1 2026 and KRW 8.08 billion in Q2 2026.
The debt-to-equity ratio stood at 15.8%, remaining in the low range of roughly 15–23% over the past four years, underscoring balance-sheet stability.
Basic infusion solutions account for more than half of sales, and the product mix is heavily weighted toward supply to hospitals and clinics.
Government reforms to drug pricing rules and policies affecting essential ("anti-discontinuation") medicines stand out as key variables for future costs and margins.
Dai Han Pharmaceutical primarily manufactures and sells basic pharmaceuticals used in hospitals and clinics, including IV infusion solutions, ampoule injections, and nutritional infusion products.
As of 2025, basic infusion solutions made up roughly 63% of sales, followed by other products at 17%, nutritional infusions at 13%, and ampoules/vials at 6%. The company also sells over-the-counter items such as contact lens solution and saline products to expand into the pharmacy retail channel.
More than 80% of supply goes to hospitals and clinics, built on a stable distribution network, and many of its products are designated as essential or anti-discontinuation medicines by the government, which places the company's focus on stable supply and quality rather than price competition.
Its production base consists of KGMP-certified facilities and automated production lines, complemented by a roughly 2,000-pyeong automated warehouse that improved inventory responsiveness and logistics efficiency.
The company holds a 5,000-pyeong site, of which the remaining 3,000 pyeong is earmarked for a new plant expansion, signaling preparation for medium- to long-term capacity growth.
In the infusion market, which has strong capital-intensive characteristics, equipment and process stability function as competitive advantages, and the company has repeatedly reinvested profits into production infrastructure rather than pursuing aggressive top-line expansion.
Since 2023, the company has operated under a sole CEO structure, with management focus centered on strengthening core competitiveness in its existing infusion and injection businesses rather than new business diversification.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩51.5B | ₩7.7B | 15.0% |
| 2025Q3 | ₩56.2B | ₩10.6B | 18.9% |
| 2025Q4 | ₩51.1B | ₩3.6B | 7.0% |
| 2026Q1 | ₩52.7B | ₩7.9B | 14.9% |
| 2026Q2 | ₩56.6B | ₩8.1B | 14.3% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩184.3B | ₩33B | ₩25B | 17.9% | 11.1% | 22.9% |
| 2023 | ₩195.9B | ₩35.8B | ₩28.4B | 18.3% | 11.5% | 18.7% |
| 2024 | ₩204.2B | ₩38.1B | ₩33.8B | 18.6% | 12.2% | 17.5% |
| 2025 | ₩208.6B | ₩31.2B | ₩27.6B | 14.9% | 9.2% | 15.8% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Consolidated revenue reached KRW 208.6 billion in 2025, continuing a four-year uptrend from KRW 184.3 billion in 2022, KRW 195.9 billion in 2023, and KRW 204.2 billion in 2024.
However, operating profit fell from KRW 38.08 billion in 2024 to KRW 31.19 billion in 2025, with the operating margin declining from 18.6% to 14.9%.
Net income attributable to owners also decreased from KRW 33.76 billion in 2024 to KRW 27.64 billion in 2025, marking a year where revenue growth and profit deceleration occurred simultaneously.
On a quarterly basis, operating profit peaked at KRW 10.64 billion in Q3 2025 before dropping sharply to KRW 3.57 billion in Q4 2025, suggesting significant cost pressure in the second half of that year.
The company then recovered to operating profit of KRW 7.86 billion in Q1 2026 and KRW 8.08 billion in Q2 2026, with revenue remaining solid at KRW 52.7 billion and KRW 56.6 billion, respectively.
Net income attributable to owners stayed in a stable range of the upper KRW 6 billion level, at KRW 6.98 billion in Q1 2026 and KRW 6.75 billion in Q2 2026.
Annual operating cash flow ranged between roughly KRW 29.0 billion and KRW 38.6 billion from 2022 to 2025, with 2025's KRW 25.6 billion on the lower end of that range. The debt ratio has continued to decline, from 22.9% in 2022 to 15.8% in 2025, reflecting a steady reduction in financial leverage.
The domestic IV infusion market is generally classified as a low-growth but relatively stable-demand industry, given its essential-medicine characteristics for hospitals and clinics. Structural factors such as population aging and rising pharmaceutical production volumes support long-term demand.
On the other hand, the government operates multiple layered post-market price management systems—drug price reevaluation, usage-price linkage, and actual transaction price cuts—aimed at fiscal soundness of the national insurance system, which continues to pressure finished-drug makers' costs and margins.
However, the government is separately pursuing a "supply-friendly pricing system" for anti-discontinuation and national essential medicines, including raising cost-reimbursement standards and offering price premiums for domestically sourced raw materials—factors that could provide a relative cushion for Dai Han Pharmaceutical given its high exposure to this category.
Industry-wide, the average operating margin over the past three years for roughly 100 domestic pharmaceutical companies (excluding CDMO firms and those with high non-reimbursed drug exposure) stood at only about 4.8%, making the company's roughly 18% average operating margin over the past decade stand out as comparatively strong profitability within the sector.
In terms of competitive structure, the domestic infusion market is understood to be an oligopoly dominated by a small number of players, with high barriers to entry given its capital-intensive nature.
That said, rather than being a high-growth industry, it functions more as a stable cash-generating business, meaning the company's growth drivers depend more on market share gains or volume increases enabled by capacity expansion.
The company has completed a roughly 2,000-pyeong automated warehouse on its 5,000-pyeong site and plans to build a new plant on the remaining 3,000 pyeong, leaving room for capacity expansion over the medium to long term.
The recovery in operating profit to KRW 7.86 billion in Q1 2026 and KRW 8.08 billion in Q2 2026, following the sharp drop in Q4 2025, suggests some easing of cost pressure.
However, the possibility of a recurrence of cost volatility similar to Q4 2025 cannot be ruled out, making it important to monitor whether margin stability is sustained in coming quarters.
Amid ongoing discussions on drug pricing reform, how the government implements raised cost-reimbursement standards and preferential treatment for domestically sourced raw materials for anti-discontinuation medicines is a variable that could directly affect the company's cost structure.
Given that the company maintains a no-debt policy and has consistently placed dividend items on its annual general shareholder meeting agenda, the future direction of shareholder-return policy also warrants attention.
Rather than rapid expansion into new products or business areas, the central strategy is likely to remain focused on production efficiency and quality competitiveness within the existing infusion and injectable business.
The current share price appears to trade at a discount relative to net asset value, implying a meaningful gap between book value and market value.
On the earnings side, results softened in 2025 relative to 2024 before showing a recovery trend across the first two quarters of 2026, meaning the market's valuation assessment may hinge on whether this recovery persists.
Dividends have consistently been placed on the agenda at annual general shareholder meetings, suggesting a stable track record of cash distribution. Given the no-debt policy, low debt ratio, and substantial cash-generating capacity, financial soundness stands out as a relatively clear strength.
No recently disclosed, specific analyst target price for this stock could be confirmed, so a market consensus valuation reference cannot be separately cited here.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
The debt ratio fell from 22.9% in 2022 to 15.8% in 2025, reflecting a nearly debt-free balance sheet. Cumulative operating profit over the past decade exceeded KRW 300 billion with an average operating margin around 18%, placing profitability near the top of the sector.
Stable operating cash flow provides the financial capacity to simultaneously reinvest in production infrastructure and pay dividends.
Many of the company's products are designated as anti-discontinuation or national essential medicines, making hospital and clinic demand relatively resistant to sudden swings. Rising social welfare demand from population aging supports a long-term demand base.
The government's separate cost-reimbursement and preferential policies for this product category also serve as a relative buffer.
The company has already completed a roughly 2,000-pyeong automated warehouse on its 5,000-pyeong site and plans to build a new plant on the remaining 3,000 pyeong, leaving room for medium-term capacity growth. KGMP-certified facilities and automated production lines support a stable mass-production system.
In the capital-intensive infusion market, facility investment can translate directly into competitive advantage.
Multiple layered post-market price control mechanisms—price reevaluation, usage-price linkage, and actual transaction price cuts—increase cost pressure across finished-drug manufacturers.
The drop in operating margin from 18.6% in 2024 to 14.9% in 2025 illustrates how these cost and policy shifts can materially affect results. Depending on how future drug pricing reforms are implemented in detail, profitability volatility could widen again.
The sharp swing in operating profit from KRW 10.64 billion in Q3 2025 to KRW 3.57 billion in Q4 2025 shows that cost factors can be concentrated in specific periods. While profits recovered in the first half of 2026, the possibility of similar volatility recurring cannot be ruled out. Raw material prices and currency fluctuations can widen quarter-to-quarter earnings variance.
Since the infusion market is regarded more as a stable cash-generating business than a high-growth one, revenue growth rates are likely to remain modest. Revenue rose every year from 2022 to 2025, but growth stayed in the low- to mid-single digits.
Absent new business ventures or rapid top-line expansion, profit growth may continue to depend heavily on cost management and production efficiency.
The government's layered post-market drug pricing mechanisms—price reevaluation, usage-price linkage, and actual transaction price cuts—can act as a persistent source of cost pressure.
Uncertainty remains over how effectively cost-reimbursement and domestic raw-material preference policies for anti-discontinuation medicines will actually be implemented. The timing and scale of policy changes could produce varying impacts on results.
Fluctuations in the prices of pharmaceutical raw materials and auxiliary supplies, along with currency movements on import-dependent inputs, directly affect the cost structure. Broad deterioration in the performance of domestic raw-material drug makers suggests rising cost pressure across the industry. A recurrence of the sharp margin decline seen in Q4 2025 cannot be ruled out.
Given the business's heavy reliance on hospitals and clinics as its primary sales channel, external variables such as medical-field strikes or reduced patient visits can temporarily affect demand.
While long-term demand for essential medicines tends to be resilient, short-term earnings can still fluctuate due to distribution or inventory adjustments at specific points in time. Long-term demand growth from population aging may not fully offset such short-term volatility.
The Q3 2026 quarterly report disclosure should be checked to see whether revenue and operating profit continue the recovery trend seen in the first half of the year.
The size of the 2026 year-end dividend and the annual general shareholder meeting agenda will indicate the direction of shareholder-return policy.
Follow-up disclosures should be checked to see whether the timeline for breaking ground on and operating the planned new plant on the 3,000-pyeong site becomes more concrete.
How the government finalizes the detailed roadmap for drug pricing reform (raised cost-reimbursement standards, domestic raw-material preferences, etc.) is a variable that will affect the cost structure.
Dai Han Pharmaceutical is a stable, cash-generating pharmaceutical company focused on IV infusion solutions and ampoule injections for hospitals and clinics; 2025 revenue rose for a fourth consecutive year, but the operating margin declined from 18.6% to 14.9%, reflecting a profit slowdown.
After operating profit fell sharply in Q4 2025, it recovered to KRW 7.86 billion and KRW 8.08 billion in Q1 and Q2 2026, respectively, suggesting some easing of cost pressure.
The debt ratio has continued to decline to 15.8%, and a decade-long average operating margin around 18% places the company's financial stability and profitability near the top of its sector.
However, government post-market drug price management systems and raw material/currency fluctuations remain persistent sources of cost pressure, and the low-growth nature of the industry may limit the pace of top-line expansion.
The planned new plant expansion and the future direction of shareholder-return policy remain medium-term watch points. Overall, the company combines a stable financial structure and essential-medicine-based demand with the potential for quarter-to-quarter earnings variability driven by policy and cost variables.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.